ReviewCell biochemistry and biophysics2025
The Significance of STAT3 in Colonic Diseases: A Comprehensive Study of Pathological Roles and Therapeutic Implications.
Review in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Cell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The transcriptional regulator signal transducer and activator of transcription 3 (STAT3) plays pivotal roles in vertebrate development and the functionality of mature tissues, particularly in modulating inflammation and immune responses. Mutations in STAT3 in humans are associated with various diseases, including immunodeficiencies, autoimmune disorders, and multiple cancers. Notably, both aberrant hyperactivation and inactivation of STAT3 are linked to disease manifestations, underscoring the need for tightly regulated STAT3 activity to maintain health. In inflammatory bowel disease (IBD), STAT3 exhibits abnormal activation in colonic tissues, primarily driven by a range of pro-inflammatory cytokines. This dysregulation compromises the integrity of the intestinal mucosal barrier and leads to an exaggerated innate immune response and heightened Th17 cell activity. Moreover, persistent STAT3 activation is implicated in the pathogenesis of colorectal cancer (CRC), highlighting its critical regulatory role in inflammation associated with cancer-induced colitis. Elevated STAT3 expression is frequently observed in CRC cases. This study delves into STAT3's multifaceted roles in various cellular processes, including proliferation, migration, differentiation, motility, and the inflammatory response, specifically focusing on their implications in colitis and colorectal cancer. We further explore therapeutic strategies to modulate STAT3 signaling pathways, which could provide innovative approaches for managing STAT3-dependent colonic disorders.
Indexed as
Identifiers
40627320What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.